Valuation: Dermapharm Holding SE

Market Cap 1.89B 2.11B 1.75B 1.58B 2.96B 201B 3B 20.92B 8.33B 105B 7.92B 7.75B 334B P/E 2026 *
14.6x
P/E 2027 * 12.9x
Enterprise Value 2.7B 3.01B 2.5B 2.26B 4.23B 287B 4.28B 29.89B 11.91B 150B 11.31B 11.07B 477B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 2.06x
Free-Float
10.7%
Yield 2026 *
2.67%
Yield 2027 * 2.98%
1 day-0.52%
1 week-1.55%
Current month-2.55%
1 month-2.92%
3 months-8.50%
6 months-16.50%
Current year-2.92%
1 week 37.8
Extreme 37.8
38.95
1 month 37.35
Extreme 37.35
39.7
Current year 34.3
Extreme 34.3
51.9
1 year 32.9
Extreme 32.9
51.9
3 years 30.15
Extreme 30.15
51.9
5 years 30.15
Extreme 30.15
91.95
10 years 21.58
Extreme 21.575
91.95
Manager TitleAgeSince
Chief Executive Officer 64 01/08/2017
Director of Finance/CFO - 01/11/2022
Investor Relations Contact - 01/12/2018
Director TitleAgeSince
Chairman 70 01/08/2017
Director/Board Member 66 01/08/2017
Director/Board Member 78 01/01/2018
Date Insider Type Main position Quantity % Market Cap. Importance
14/5/26 Buy

Chairman

380,000 0.7670%
7/1/26 Buy 150 0.0003%
7/1/26 Buy 150 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.52%-1.55%+17.54%+3.41% 2.12B
+0.50%+1.38%+57.09%+129.96% 1,143B
+0.86%+5.14%+45.00%+86.15% 647B
-0.14%+0.42%+25.69%+105.85% 506B
-0.05%+1.73%+52.74%+67.74% 384B
-0.63%-5.97%+61.93%+37.06% 350B
+0.34%+1.84%+30.70%+54.27% 293B
-0.45%+1.19%+2.89%+26.08% 265B
+0.87%+3.08%+54.69%+72.74% 242B
+0.08%+3.67%+35.05%+107.78% 197B
Average +0.09%+1.15%+38.33%+69.10% 402.97B
Weighted average by Cap. +0.25%+1.55%+44.48%+88.97%

Financials

2026 *2027 *
Net sales 1.21B 1.35B 1.12B 1.01B 1.89B 128B 1.91B 13.36B 5.32B 67.13B 5.05B 4.95B 213B 1.25B 1.4B 1.16B 1.05B 1.96B 133B 1.99B 13.87B 5.52B 69.68B 5.25B 5.14B 221B
Net income 137M 153M 127M 115M 215M 14.57B 217M 1.52B 604M 7.62B 574M 562M 24.2B 155M 173M 144M 130M 243M 16.49B 246M 1.72B 684M 8.63B 650M 636M 27.39B
Net Debt 812M 905M 750M 680M 1.27B 86.17B 1.29B 8.97B 3.57B 45.09B 3.4B 3.32B 143B 687M 766M 635M 575M 1.07B 72.91B 1.09B 7.59B 3.02B 38.15B 2.87B 2.81B 121B
Projected Income Statement - Annual - Dermapharm Holding SE
Logo Dermapharm Holding SE
Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Employees
3,619
Date Price Change Volume
28/10/26 EUR 38.20 -0.52% 15,757
27/10/26 EUR 38.40 +1.45% 11,217
26/10/26 EUR 37.85 -1.43% 10,131
23/10/26 EUR 38.40 -0.78% 18,324
22/10/26 EUR 38.70 -0.26% 9,838
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Dermapharm Holding SE
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
38.20EUR
Average target price
51.00EUR
Spread / Average Target
+33.51%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Dermapharm Holding SE